CPRX
NASDAQ HealthcareCatalyst Pharmaceuticals, Inc. - Common Stock
Biotechnology
Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing medicines for patients living with rare diseases in the United States. It offers Firdapse for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); Fycompa, a novel non-competitive selective antagonist at the postsynaptic ionotropic alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid glutamate receptor that is used to treat focal onset seizures, as well as tonic-clonic seizure; and AGAMREE, a corticosteroid for the treatment of duchenne muscular dystrophy. The company has license agreements with BioMarin Pharmaceutical Inc.; and a collaboration and license agreement with Endo Ventures Limited for the development and commercialization of generic Sabril tablets. Catalyst Pharmaceuticals, Inc. was founded in 2002 and is based in Coral Gables, Florida.
๐ Market Data
| Price | $28.74 |
|---|---|
| Volume | 1,389,744 |
| Market Cap | 3.51B |
| Beta | 0.660 |
| RSI (14-Day) | 69.9 |
| 200-Day MA | $22.71 |
| 50-Day MA | $24.99 |
| 52-Week High | $32.56 |
| 52-Week Low | $19.05 |
| P/E Ratio | 17.11 |
| Forward P/E | 9.17 |
| Price / Book | 3.69 |
๐ฏ Investment Strategy Scores
CPRX scores across each investment strategy. Higher is better for that strategy's goals.
๐ Strategy Interpretation
Best fit: ๐ Over-Hyped (82/100) โ this strategy Overbought stocks (potential short candidates).
Lowest fit among scored strategies: ๐ช Falling Knife (13/100). No single score is a buy or sell signal โ use multiple lenses together. Learn how to read these scores โ
๐ Learn More
Indicators on this page
Educational articles
Find CPRX in your text
Paste any article, transcript, or post โ the tool will extract CPRX and every other hidden ticker.
Disclaimer: This data is for educational and entertainment purposes only and does not constitute financial advice. Market data may be delayed. Always do your own research before making investment decisions.
Data last updated: 2026-05-01.